Healthcare industry

Microrobots have the potential to revolutionize medicine. Researchers at the Max Planck ETH Centre for Learning Systems have now developed an imaging technique that for the first time recognises cell-sized microrobots individually and at high resolution in a living organism. This is an important step towards precise control of the robots and their clinical translation.

Junior Professor Dr Daniela Duarte Campos has been awarded a substantial grant from the Federal Ministry of Education and Research (BMBF). She and her junior research group are investigating bioprinting for tissue and organ engineering at the Center for Molecular Biology of Heidelberg University and at the “3D Matter Made to Order” Cluster of Excellence, a collaboration between Ruperto Carola and Karlsruhe Institute of Technology (KIT).

Intelligent Diagnostics - 09/02/2022

AI for added value in digital melanoma diagnostics

Intelligent Diagnostics is an interdisciplinary project that brings together the latest technologies and research institutes to better support doctors in diagnosing skin cancer through innovative imaging and artificial intelligence.

Laboratory automation - 29/11/2021

Reaching the goal quickly and efficiently with the help of artificial intelligence

Medical research is slow, costly and time-consuming. The system developed by the start-up LABMaiTE could soon change that. With the help of artificial intelligence, it will be possible to automate laboratory experiments and collect and analyse data at the same time.

Furtwangen University publishes the world’s first molecular biological study on bacterial contamination of slit lamps. Slit lamps are among the most important tools used by ophthalmologists and opticians. They allow selected areas of the eye to be magnified and examined for diseases.

rMSI technology - 08/11/2021

New multispectral imaging technology improves endoscopic tumour detection capabilities

The quality of minimally invasive surgery depends to a large extent on the imaging properties of the endoscopes used. The Mannheim-based company Thericon GmbH has developed a multispectral imaging technology that overlays views from multiple light channels in real time to create a detailed image on which tumours can be better identified.

Neurodegenerative diseases - 30/09/2021

Artificial intelligence enables early diagnosis of dementia

We are all afraid of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Yet, therapies are increasingly becoming available. Although they do not cure what causes a disease, they can at least slow down its progression, provided it is diagnosed as early as possible. The Tübingen-based start-up AIRAmed has developed software that uses artificial intelligence to measure and detect changes in the brain long before they…

Digitalisation - 04/08/2021

Eye check for all - quick and easy thanks to artificial intelligence

Many eye diseases are already easily treatable, if they are detected in time. But waiting months for an ophthalmologist’s appointment seems to be the norm - that is, if you can get to see a specialist at all. The Tübingen-based start-up eye2you wants to improve this situation: it has developed a mobile retinal examination device involving a smartphone and AI. It can be used by family doctors, diabetologists and nursing staff and thus help to…

Age-related macular degeneration (AMD) is the commonest cause of blindness in developed countries affecting seven million in total in Germany, from which 500,000 people are suffering from late stage disease, around half of whom are registered as visually impaired. There are two forms of AMD, ‘wet’ and ‘dry’. There are currently no treatments available for the dry form of the disease (geographic atrophy).

Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an…

Smallest 3D printed miniature endoscope in the world detects cholesterol plaques and thrombs inside human and mouse arteries.

Microstructure Technology - 17/07/2020

An electronic nose for many applications

Sensory organs are sophisticated masterpieces of nature. That is why humans have often tried to copy them. Be it cameras or microphones - there are technical objects that have always been based on natural models such as the eye or the ear. For a long time, however, no artificial sense of smell has featured in the technical repertoire. Now researchers at the Karlsruhe Institute of Technology (KIT) have developed an electronic nose. It can…

Vaccine development - 02/06/2020

CureVac as a pioneer of mRNA technology – what is behind the novel COVID-19 vaccine?

All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…

Multiple sclerosis - 12/03/2020

Direct application of biopharmaceuticals through the nose into the brain

There is currently no cure for multiple sclerosis, the most common neurological autoimmune disease in humans. Biopharmaceuticals that can delay the course of the disease or diminish its effects are often prevented from being fully effective by the blood-brain barrier. A European consortium led by the Fraunhofer IGB, Stuttgart is developing a new technology that can transport an innovative active ingredient directly to the central nervous system.

Article - 08/11/2019

Nanorobots as future minimally invasive tools for the eye

It is difficult to place drugs in the right place in the eye. When using droplets, only a small fraction of the drug reaches its target. Injecting drugs into the eye is also more a matter of luck than judgement. Basic researchers at the Max Planck Institute for Intelligent Systems Stuttgart have developed a nanorobot that can be loaded with active ingredients for treating eye diseases and directed through the solid tissue of the vitreous body.

Article - 07/02/2019

Artificial intelligence in ophthalmology

Retinal diseases such as age-related macular degeneration (AMD) are now treatable. However, it is hard to predict individual disease progression. A group of researchers at the University Eye Centre in Freiburg are currently developing a new system which is hoped will allay fears and improve therapy planning. The system uses artificial intelligence to predict therapeutic outcome from image and patient data. Initial results are already available.

Article - 21/08/2018

Parkinson's disease: vitamin B3 has a positive effect on nerve cells

Parkinson's disease is one of the most common neurodegenerative diseases in the world. There are around 4.1 million sufferers worldwide. It is characterised by motor impairments that result from the death of certain nerve cells in the brain. Researchers at the University of Tübingen have now discovered that vitamin B3 has a positive effect on damaged nerve cells and can boost their energy metabolism.

Article - 13/06/2018

TeleDerm: Rapid help from a dermatologist via teleconsultation

Some geographical locations have relatively few specialist medical practices. Getting an appointment with a specialist if you live in such areas might mean a long wait or a long journey. A study being carried out at the University of Tübingen is looking to improve this situation: the TeleDerm project involves dermatologists using telemedicine to assess skin disorders from images taken by GPs.

Big Data - 13/03/2018

“More data does not automatically imply more knowledge“

In Germany, one of the big names in evidence-based medicine is Prof. Dr. rer. nat. Gerd Antes, co-director of Cochrane Germany. In the following interview, Antes talks about the hype surrounding big data, warns against false promises and reminds us about what is taken for granted.

Article - 14/02/2018

Animal-free diabetes research with the pancreas chip

Quite a number of promising drug candidates for the treatment of diabetes are currently in the pharmaceutical pipeline, including innovative drugs that can stimulate the regeneration of insulin-producing pancreatic cells. However, they will have to be safety tested in animals. Scientists from Ulm University Hospital have now begun to develop a pancreatic chip from stem cells.

Company profile - 04/09/2017

Mireca: a new drug for stopping the progression of eye diseases

A team of researchers from several EU countries has developed a new drug that stops the progression of hereditary retinal diseases. The project partners founded a company called Mireca Medicines GmbH in the city of Tübingen to bring the drug to market.

Press release - 06/04/2017

Start-up in the garage – a location with prospects

Newly established start-up wins award – Mireca Medicines GmbH develops treatment for hereditary eye disease and receives Innovation Award of the biotechnology regions in Germany

Company profile - 09/01/2017

Novaliq to develop innovative eye drop products

A remedy is now available for people suffering from dry eye disease. Novaliq GmbH, a specialty pharmaceuticals company from Heidelberg, has developed a highly innovative technology platform for producing innovative drugs to eliminate common eye conditions that cause itching, burning and a feeling of pressure on the eye. The new drug delivery platform not only opens up groundbreaking new prospects for ophthalmology, but also for dermatology.

Article - 08/11/2016

Towards at-home genetic testing

The ability to detect a broad range of conditions and modifications in human, animal, plant and pathogen genes is highly important in the field of medicine for diagnosing diseases and starting therapy as quickly as possible. Chemists at the University of Konstanz have now developed a genetic test that does not need to be carried out in the laboratory and can be evaluated with the naked eye, similar to a pregnancy test. The test would therefore be…

Article - 10/10/2016

Teva plans the large-scale production of monoclonal antibodies in Ulm

Teva is investing heavily in its biotechnological production site in Ulm. On behalf of BIOPRO Baden-Württemberg, Walter Pytlik spoke with Dr. Hermann Allgaier, CEO of Teva Biotech, about the importance of biotechnology for the Group and about Teva in general. The company is headquartered in Israel.